Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
27.47
-0.31 (-1.12%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Denali Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | 1.27 | 330.53 | 108.46 | 48.66 | 335.66 | 26.68 | Upgrade
|
| Revenue Growth (YoY) | -99.63% | 204.74% | 122.90% | -85.50% | 1158.19% | -79.34% | Upgrade
|
| Cost of Revenue | 422.61 | 423.88 | 358.73 | 265.35 | 212.62 | 193.38 | Upgrade
|
| Gross Profit | -421.34 | -93.35 | -250.27 | -216.69 | 123.04 | -166.7 | Upgrade
|
| Selling, General & Admin | 100.52 | 103.35 | 90.48 | 79.06 | 60.33 | 46.48 | Upgrade
|
| Research & Development | -26.65 | - | - | - | - | - | Upgrade
|
| Operating Expenses | 73.87 | 103.35 | 90.48 | 79.06 | 60.33 | 46.48 | Upgrade
|
| Operating Income | -495.21 | -196.7 | -340.74 | -295.75 | 62.72 | -213.18 | Upgrade
|
| Interest & Investment Income | 7.55 | 7.55 | 13.14 | 13.34 | 5.7 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 8.36 | - | - | - | 3.6 | 10.2 | Upgrade
|
| EBT Excluding Unusual Items | -479.3 | -189.15 | -327.61 | -282.41 | 72.01 | -202.98 | Upgrade
|
| Gain (Loss) on Sale of Investments | 45.14 | 43.95 | 1.64 | -8.75 | -0.06 | 5.02 | Upgrade
|
| Pretax Income | -419.62 | -145.19 | -325.97 | -291.16 | 71.96 | -197.97 | Upgrade
|
| Income Tax Expense | 0.03 | 0.03 | 0.02 | -0.58 | 0.82 | -0.35 | Upgrade
|
| Net Income | -419.65 | -145.22 | -325.99 | -290.58 | 71.14 | -197.61 | Upgrade
|
| Net Income to Common | -419.65 | -145.22 | -325.99 | -290.58 | 71.14 | -197.61 | Upgrade
|
| Shares Outstanding (Basic) | 149 | 137 | 126 | 122 | 109 | 96 | Upgrade
|
| Shares Outstanding (Diluted) | 149 | 137 | 126 | 122 | 113 | 96 | Upgrade
|
| Shares Change (YoY) | 12.10% | 9.43% | 3.30% | 7.83% | 17.88% | 3.22% | Upgrade
|
| EPS (Basic) | -2.83 | -1.06 | -2.60 | -2.39 | 0.65 | -2.07 | Upgrade
|
| EPS (Diluted) | -2.83 | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 | Upgrade
|
| Free Cash Flow | -402.1 | -370.93 | -262.55 | -219.89 | 413.06 | -169.5 | Upgrade
|
| Free Cash Flow Per Share | -2.71 | -2.70 | -2.09 | -1.81 | 3.67 | -1.77 | Upgrade
|
| Gross Margin | - | -28.24% | -230.74% | - | 36.66% | - | Upgrade
|
| Operating Margin | -39085.40% | -59.51% | -314.16% | -607.78% | 18.69% | -799.10% | Upgrade
|
| Profit Margin | -33121.86% | -43.94% | -300.56% | -597.15% | 21.19% | -740.74% | Upgrade
|
| Free Cash Flow Margin | -31736.31% | -112.22% | -242.06% | -451.88% | 123.06% | -635.34% | Upgrade
|
| EBITDA | -494.61 | -187.87 | -330.36 | -287.16 | 71.25 | -205.19 | Upgrade
|
| EBITDA Margin | - | -56.84% | - | - | 21.23% | - | Upgrade
|
| D&A For EBITDA | 0.6 | 8.83 | 10.38 | 8.59 | 8.53 | 7.99 | Upgrade
|
| EBIT | -495.21 | -196.7 | -340.74 | -295.75 | 62.72 | -213.18 | Upgrade
|
| EBIT Margin | - | -59.51% | - | - | 18.68% | - | Upgrade
|
| Effective Tax Rate | - | - | - | - | 1.14% | - | Upgrade
|
| Revenue as Reported | 1.27 | 330.53 | 108.46 | 48.66 | 335.66 | 26.68 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.